"In trials spanning 47 patients across Europe and the U.S., 80% demonstrated meaningful improvement in visual acuity and were able to read letters, numbers, and words, the company says. "To my knowledge, this is the first time that restoration of the ability to fluently read has ever been definitively shown in blind patients," Hodak told TechCrunch in an interview in December."
"In the short-term, Science Corp. is betting on PRIMA, a chip said to be smaller than a grain of rice that, when implanted in the eye, works with camera-equipped glasses to restore functional vision to people suffering from advanced macular degeneration."
"It isn't clear when PRIMA will be available to patients, but the regulatory path is taking shape. Science Corp. has submitted a CE mark application for the implant to the European Union, and says it expects an approval in mid-2026, following which it'll launch the product in the continent."
Science Corporation, founded by Max Hodak from Neuralink, is developing PRIMA, a miniature brain-computer interface implant designed to restore vision for people with advanced macular degeneration. The company acquired PRIMA's assets from French company Pixium Vision in 2024 and completed clinical trials involving 47 patients across Europe and the U.S. Results showed 80% of participants achieved meaningful improvements in visual acuity and could read letters, numbers, and words. Science Corporation raised $230 million in Series C funding at a $1.25 billion valuation. The company has submitted a CE mark application to the European Union and expects approval by mid-2026, positioning it as potentially the first brain-computer interface company to bring a product to market.
Read at TechCrunch
Unable to calculate read time
Collection
[
|
...
]